Laboratory Testing for Cirrhosis
For adults with suspected or confirmed cirrhosis, obtain baseline testing with bilirubin, albumin, ALT, ALP, GGT, and complete blood count, followed by a comprehensive liver etiology screen including abdominal ultrasound, viral hepatitis serologies, autoantibodies, immunoglobulins, and iron studies. 1
Baseline Laboratory Panel
Initial Liver Function Tests
- Bilirubin (total and direct) 1
- Albumin 1
- Alanine aminotransferase (ALT) 1
- Alkaline phosphatase (ALP) 1
- γ-glutamyltransferase (GGT) 1
- Complete blood count (if not performed within previous 12 months) 1
These tests should be interpreted in the context of previous results, past medical history, and current clinical condition, as the extent of abnormality does not necessarily correlate with clinical significance. 1
Comprehensive Liver Etiology Screen
All patients with abnormal liver tests should undergo a standard liver etiology screen regardless of the level or duration of abnormality. 1 This includes:
Imaging
- Abdominal ultrasound to assess liver parenchyma, splenomegaly, and portal hypertension 1
Viral Hepatitis Testing
Autoimmune Markers
- Anti-mitochondrial antibody 1
- Anti-smooth muscle antibody 1
- Antinuclear antibody 1
- Serum immunoglobulins 1
Iron Studies
- Serum ferritin and transferrin saturation (obtained simultaneously) 1
Additional Baseline Tests for Cirrhosis Assessment
Beyond the standard etiology screen, patients with confirmed or suspected cirrhosis require:
- Aspartate aminotransferase (AST) to calculate the AST/ALT ratio, which when >1 indicates advanced fibrosis/cirrhosis 1
- Prothrombin time/INR to assess synthetic liver function 2, 3
- Platelet count (already included in CBC) - values <160 × 10³/μL significantly increase likelihood of cirrhosis (LR 6.3) 4
A platelet count, AST/ALT ratio, and INR can be combined to predict cirrhosis with high accuracy. 5 The Lok index using these parameters has an LR of 0.09 for excluding cirrhosis when <0.2. 4
Follow-Up Laboratory Monitoring
Routine Monitoring Frequency
Patients with confirmed cirrhosis require regular laboratory monitoring to detect decompensation and guide management. The specific tests and their changes over time are critical predictors of clinical outcomes. 6
Key Variables to Monitor
- Platelet count - progressive decline predicts decompensation 6, 7
- AST/ALT ratio - worsening ratio predicts liver-related death/transplant 6
- Total bilirubin - severe worsening predicts decompensation 6
- Albumin - declining levels predict both decompensation and mortality 6, 7
Both the baseline value and the rapidity of change in these laboratory variables are important in predicting clinical outcomes. 6 Severe worsening of platelet count, bilirubin, and albumin over 2 years significantly increases risk of clinical decompensation. 6
Monitoring for Specific Complications
Hepatocellular Carcinoma Surveillance
- Alpha-fetoprotein (AFP) every 6 months in combination with abdominal ultrasound for high-risk patients with cirrhosis 8
- This applies to cirrhosis from HBV, HCV, genetic hemochromatosis, and males with alcohol-related or primary biliary cirrhosis 8
Renal Function Monitoring
- Serum creatinine to detect acute kidney injury using adapted KDIGO criteria 2
- AKI in cirrhosis is defined as SCr increase ≥0.3 mg/dL within 48 hours OR ≥50% increase from baseline within 3 months 2
- Baseline creatinine should be from the last 7 days or up to 3 months prior 2
Coagulation Assessment
Do NOT routinely correct abnormal INR, APTT, platelet count, or fibrinogen with blood products or factor concentrates to prevent spontaneous bleeding, as this is not recommended. 9 Conventional coagulation tests do not adequately reflect true bleeding or thrombosis risk in cirrhosis. 10
Clinical Context and Pitfalls
Important Caveats
The magnitude of liver enzyme elevation does not determine clinical significance - this is determined by which specific analyte is abnormal and the clinical context. 1 For example, both AST and ALT can be normal even in established cirrhosis, yet the AST/ALT ratio remains useful for fibrosis assessment even when both values are within normal range. 1
Creatinine-based formulas overestimate GFR in cirrhosis, leading to underestimation of renal dysfunction. 2 Do not use imputed creatinine values in cirrhotic patients. 2
Risk Stratification Tools
For patients with suspected cirrhosis, non-invasive fibrosis scores improve diagnostic accuracy:
- Bonacini cirrhosis discriminant score >7 (LR 9.4 for cirrhosis) 4
- FIB-4 or NAFLD Fibrosis Score for NAFLD patients 1
- Lok index <0.2 effectively excludes cirrhosis (LR 0.09) 4
Physical Examination Findings
While laboratory tests are primary, certain physical findings increase cirrhosis likelihood: